🧠🍽️ Obesity and being overweight are often talked about like personal failures, but the science tells a very different story. In this episode of The Health Curve Podcast, Dr. Jason Arora and Dr. Marc-André Cornier (Past President of The Obesity Society, Professor of Medicine, and Director of the Division of Endocrinology at MUSC) explore obesity as a chronic, progressive disease shaped by biology 🧬 and an “obesogenic” environment.
Together, they unpack why obesity rates have risen so dramatically worldwide, how risk and complications vary across populations 🫀, and why low socioeconomic environments and “food deserts” can quietly stack the odds against health 🏙️. They also discuss why childhood obesity is so concerning 🧒📱, and what it means for long-term health systems, productivity, and society.
They also explore what evidence-based obesity care actually looks like today, walking through the full toolbox - from lifestyle foundations 🥗🏃 and medications (including GLP-1–based therapies) 💉 to bariatric surgery 🏥 , plus the hard truth that long-term disease often requires long-term treatment ⏳. They also tackle common fears and criticisms: side effects, cost and access 💸, direct-to-consumer “quick fixes” 🧪, and the tension between prevention and treatment.
If you’ve ever wondered why weight loss can feel like your body is fighting you - and what a smarter, more compassionate, science-based approach looks like - this episode is for you 💙.
Chapters"
00:00 – Introduction and guest background
01:10 – Why obesity is rising: genes × “obesogenic” environments
03:15 – Why obesity risk differs across populations and regions
04:20 – Visceral vs subcutaneous fat: metabolic vs mechanical health impacts
05:50 – The environmental drivers: food deserts, safety, inactivity, marketing
06:55 – Why childhood obesity is accelerating
08:20 – The societal and economic spillovers of obesity
10:50 – Why obesity meets the definition of a chronic disease
13:05 – Patient archetypes: cosmetic vs health vs “not on the radar”
14:30 – The obesity treatment toolbox: lifestyle, meds, surgery, teams
20:00 – Who should get what? BMI limits, waist measures, risk staging
23:35 – Expected weight-loss ranges: lifestyle vs GLP-1s vs surgery
26:10 – Long-term challenges: cost, coverage, adherence, access
29:15 – Side effects and safe prescribing: why supervision matters
31:35 – Direct-to-consumer risks, compounded meds, and regulation
33:45 – Prevention vs treatment: why it’s not either/or
36:30 – “Big food vs big pharma” concerns and stigma
39:50 – The future of obesity care: primary care, centers, virtual models
43:20 – What’s next in meds: multi-agonists, longer-acting options, muscle preservation